If you look at the drug center, they lost about a third of the reviewers that review breast and gynecological cancer products. They lost more than half of the group that reviews malignant heme products. They've seen 473 departures of medical reviewers, voluntary departures, on top of about 600 RIFs. That's more than 20% at center. So you're seeing a hollowing out of the scientific staff at the fda, and that's starting to impact early reviews. (08:01–08:08)
CLAIM
Asserts that there have been 473 voluntary departures of medical reviewers, plus about 600 RIFs.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
